TTP Group Limited (“TTP”), a technology and product development firm, has sold Cellular Highways Limited (“Cellular Highways”) to StemCell Technologies Inc. (“StemCell”), a developer of life science research products and a growing number of cGMP offerings.
Cellular Highway’s will meaningfully expand StemCell’s existing cell isolation and culture product lines, accelerating innovation in the development of life-changing cell and gene therapies. It strongly aligns with StemCell’s strategic growth in the cell therapy space.
Cellular Highways, based in Cambridge, United Kingdom, is a life sciences company focused on revolutionizing cell sorting through its proprietary VACS™ (Vortex-Actuated Cell Sorting) technology. VACS™ is a gentle, high-speed, multiparametric cell sorting in a closed, sterile system through microfluidic vortices.
TTP, founded in 1987, is an independent UK-based technology and product development consultancy. The firm supports clients ranging from startups to global corporations in solving complex challenges and bringing innovative, commercially viable products to market.
StemCell, based in Vancouver, Canada, supports life sciences research with more than 2,500 specialized reagents, tools, and services. StemCell offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
EC M&A acted as the exclusive advisor to TTP on this transaction.